FluoroPharma Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 4
Employees
  • Stock Symbol
  • FPMI
Stock Symbol
  • Investments
  • 1

FluoroPharma General Information

Description

FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.

Contact Information

Formerly Known As
Commercial E-Waste Management
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Therapeutic Devices
Stock Exchange
PINX
Primary Office
  • 8 Hillside Avenue
  • Suite 108
  • Montclair, NJ 07042
  • United States
+1 (973) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

FluoroPharma Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
73.4K

FluoroPharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2016 FY 2016 31-Dec-2016 FY 2015 31-Dec-2015 FY 2014 31-Dec-2014
EV 9,412 9,412 12,648 12,998
Revenue 0 0 0 0
EBITDA (744) (744) (2,244) (3,984)
Net Income (2,050) (2,050) (3,164) (4,131)
Total Assets 335 335 839 820
Total Debt 5,825 5,825 4,349 2,123
Public Fundamental Data provided by Morningstar, Inc. disclaimer

FluoroPharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore FluoroPharma‘s full profile, request access.

Request a free trial

FluoroPharma Executive Team (5)

Name Title Board Seat Contact Info
Thomas Tulip Ph.D Chief Executive Officer, Board Member & President
Tamara Rhein Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Edward Lyons Jr. Vice President
You’re viewing 3 of 5 executive team members. Get the full list »

FluoroPharma Board Members (7)

Name Representing Role Since
Andrew Sassine Self Board Member 000 0000
Joseph Pierro MD Self Board Member 000 0000
Lawrence Atinsky JD FluoroPharma Board Member 000 0000
Peter Conti Ph.D FluoroPharma Board Member 000 0000
Walter Witoshkin FluoroPharma Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

FluoroPharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

FluoroPharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore FluoroPharma‘s full profile, request access.

Request a free trial

FluoroPharma Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000 00000 09-Jun-2016 000000000000000000 Biotechnology 000000 00000 00.0
To view FluoroPharma’s complete acquisitions history, request access »

FluoroPharma Subsidiaries (1)

Company Name Industry Location Founded
000000 00000 00000 Biotechnology Lincoln, NE 0000
To view FluoroPharma’s complete subsidiaries history, request access »